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Abstract: Targeted alpha-particle therapy (TAT) aims to selectively deliver radionuclides emitting
α-particles (cytotoxic payload) to tumors by chelation to monoclonal antibodies, peptides or small
molecules that recognize tumor-associated antigens or cell-surface receptors. Because of the high linear
energy transfer (LET) and short range of alpha (α) particles in tissue, cancer cells can be significantly
damaged while causing minimal toxicity to surrounding healthy cells. Recent clinical studies have
demonstrated the remarkable efficacy of TAT in the treatment of metastatic, castration-resistant prostate
cancer. In this comprehensive review, we discuss the current consensus regarding the properties of the
α-particle-emitting radionuclides that are potentially relevant for use in the clinic; the TAT-mediated
mechanisms responsible for cell death; the different classes of targeting moieties and radiometal
chelators available for TAT development; current approaches to calculating radiation dosimetry
for TATs; and lead optimization via medicinal chemistry to improve the TAT radiopharmaceutical
properties. We have also summarized the use of TATs in pre-clinical and clinical studies to date.
Keywords: targeted alpha-particle therapy; solid tumors; mechanism of cell death; targeting moieties;
chelation; radiation dosimetry; medicinal chemistry; clinical studies
1. Introduction
Over the past two decades, radioimmunotherapy (RIT) has proven to be an effective treatment
for non-solid tumors (reviewed in [1,2]); e.g., radiolabeled anti-CD20 monoclonal antibodies for the
Molecules 2019, 24, 4314; doi:10.3390/molecules24234314 www.mdpi.com/journal/molecules
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treatment of lymphoma. These antibody-radionuclide conjugates have typically used beta (β)-particle
emitting radionuclides; e.g., 131I, 67Cu, 177Lu or 90Y. However, due to the relatively long range of the
associated β-emissions and the poor tumor penetration of antibodies, there has been concern regarding
the use of RIT for treatment of solid tumors, where much of the energy is deposited in the surrounding
normal tissues relative to the tumor, particularly in the case of small tumor cell foci or metastases [1].
Alpha (α)-particle-emissions have a much shorter range and greater linear energy transfer (LET)
relative to β-emissions, depositing more energy into smaller volumes [3]. Hence, there has been
significant interest in the development of targeted alpha-particle therapy (TAT) for the treatment of
solid tumors. Recently, the FDA approved the use of 223RaCl2 (Xofigo®) for the palliative care of
prostate bone metastases, and the efficacy of 223RaCl2 and 225Ac–PSMA–617 have been demonstrated
in the treatment of prostate bone metastases (Figure 1) [4–6]. These developments have further elevated
interest in the development of novel α-emission cancer treatments [7,8]. Typically, TAT for solid
tumors involves attaching an α-particle-emitting radionuclide to a tumor targeting scaffold, followed
by the intravenous administration and systemic targeting of tumors and metastases. The α-particle
range is only a few cell diameters, ensuring that the greatest effect of tumor TAT remains within the
tumor volume [3]. Herein we discuss the current progress, challenges and approaches toward the
development of novel TATs for the treatment of solid tumors.
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thus, have hundreds fold higher LET (α = 100 keV/µm versus β = 0.2 keV/µm) [11–14]. Hence, α-
emissions deposit large amounts of energy in a smaller volume relative to β-emissions and result in 
the direct breaking of covalent bonds; e.g., DNA double-strand breaks. In either case (α or β), the 
DNA damage can activate DNA damage checkpoints and double-strand break repair [15]. Where the 
damage is significant or if there are defects in the checkpoint or repair pathways such that repairs 
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Figure 1. 68Ga-PSMA-11 PET/CT images of a treatment-naïve patient with extensive bone metastasis at
primary diagnosis. A complete remission was observed after three cycles of 225Ac-PSMA-617 with
de-escalating activities of 8/7/6 MBq. The patient remained symptom-free with undetectable serum
PSA and a negative 68Ga-PSMA-11 PET/CT at 11-month follow-up evaluation. This figure and legend
were reproduced from Sathekge, et al. [6].
There are differences in the mechanism of tumor cell killing when comparing β-emission to
α-emission therapies. β-particles scale to the size of electrons, travel over a relatively longer range
(0.5–12 mm) in tissues in comparison to α-particles, have relatively lower LET and generate hydroxyl
free-r dicals by breaking ovalent bonds of wat r molec les in the ti sue [9]. These free radicals
resul in oxid tive d mage to the cellular DNA macr molecules, causing double-strand breaks [10].
In contrast, α-particles are heavier (size of He ato ), travel over a much shorter range (40–90 µm),
and thus, have hundreds fold higher LET (α = 100 keV/µm versus β = 0.2 keV/µm) [11–14]. Hence,
α-emissions deposit large amounts of energy in a smaller volume relative to β-emissions and result
in the direct breaking of covalent bonds; e.g., DNA double-strand breaks. In either case (α or
β), the DNA damage can activate DNA damage checkpoints and double-strand break repair [15].
Where the damage is significant or if there are defects in the checkpoint or repair pathways such that
repairs cannot be made, i.e., irr parable damage, programmed cell eath ( poptosis) is initiated [16].
In apoptosis-deficient tumor cells, the resulting damage to the cellular machinery eventually results
in necrotic cell death [16]. Hence, α-emission therapy potentially has several distinct advantages
relative to β therapy. First, the shorter range of α-emissions result in lower off-target damage but will
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still allow for killing of adjacent tumor cells. Since tumors are known to be heterogeneous in marker
expression [17], nearby cells that do not express the target can also be damaged and killed, potentially
eliminating a mechanism of resistance; i.e., killing of marker expressing cells with the clonal expansion
of non-marker expressing cells. Second, the greater energy deposition will result in greater DNA
damage and a correspondingly greater level of cell killing. Third, α-emission-mediated DNA damage
does not rely on the generation of free radicals, potentially eliminating the development of a major
mechanism of resistance to radiation therapy; e.g., upregulation of superoxide dismutase, etc. [3].
There are many α-emitting radionuclides available for use in the development of TAT, and factor,
including nuclear characteristics, availability, chemistry, specific activity, synthesis yield, chemical and
biological stability of conjugates, and costs, need to be considered. Choice of targeting scaffold is also
a major consideration in TAT development. Antibodies, antibody fragments, peptides and passive
targeting strategies have been employed and the type of targeting moiety chosen will have a bearing
on the type of radionuclide attachment used, the route of clearance and blood pharmacokinetics (PK),
tissue biodistribution (BD) and radiation dosimetry. The relative merits of available radionuclides,
attachment chemistries and targeting moieties are discussed herein. Radiation dosimetry (RD) is an
area of key importance in development of TATs. The discrete decay chains of some α-particle-emitting
radionuclides involve the generation of daughter products with individual radioactive emission
properties. Hence, the biological fate of the daughter products and resulting tissue exposure to ionizing
radiation is a major concern that must be evaluated and the current status of RD studies in the context
of TAT development are also discussed. Strategies for lead optimization via medicinal chemistry to
improve the TAT radiopharmaceutical properties and methods of current good manufacturing practice
(cGMP) production are discussed. Also included are brief reviews of preclinical and clinical TAT
studies conducted to date.
2. Mechanism of Action/Tumor Cell Killing
Since the discovery of radioactive materials, the effect of radiation on the properties of matter has
been of significant interest in the disciplines of material science, geology and astrophysics. For example,
the first large-scale effect of radiation on solid material was observed by E.P. Wigner via exposure
to a nuclear fission reactor, and that was thus named the Wigner effect, or “Wigner’s disease” [1].
Since then, the large spread of medical technology involving sources of ionization radiation [2] and
the development of nuclear weapons has caused a spike in studies on the effect of radiation on living
tissue. That work increased our understanding of the concept of radiation risk and created new fields
of scientific study; for example, radiation health safety, radiation dosimetry and radiation oncology.
Because of the high energy of α-particles and stochastic nature of ionization radiation, their effects
may be observed on all levels of a biological system. Any molecule, cell, tissue or organ can display
α-decay radiation damage, and such damage can be localized, or occur throughout the entire body of
any multicellular organism [3].
The first step in producing radiation effects is the generation of a primary recoil atom and
α-particles by a radioactive decay. Such events take place very rapidly in much less than 1 fs [4]. In the
case of α-decay of radiopharmaceutical isotopes of interest, the average kinetic energy per recoil atom
is ~100 keV, and the average kinetic energy deposited within the range of a single α-particle is 5 MeV.
It is clear that the relatively high levels of energy deposited by the combination of the fast-moving
heavy ions and high energy α-particles can cause large amounts of damage to solid matter. There are
many methods to estimate the effect of radiation in solid materials; e.g., the stopping theory based on
coulombic interactions, molecular dynamics and transport theory. However, unlike solid materials,
biological tissues do not consist of solid crystalline structures, and this significantly increases the
complexity of estimating the effects of α-decay (as well as other ionization radiation), making the
application of the aforementioned methods impossible or extremely difficult numerically. To overcome
such limitations, a semi-quantitative approach has been applied. First, the biological effects observed
in irradiated subjects were separated into one of two categories [3,6]: deterministic effects, which have
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a practical threshold absorption dose below which effects are negligible or not evident; and stochastic
effects, where the relationship between dosage and severity of effect is either less evident or absent.
Maintaining the integrity of many different types of macromolecular structures is important to cell
viability and all cellular organic molecules are subject to damage by ionizing radiation. However, the
genomic DNA molecules are considered to be the most critical targets for the biological effects of ionizing
radiation because intact DNA is required for cellular replication and damaged but repaired DNA can
result in the fixation of genetic mutations that can affect normal cellular function and viability [18].
Ionizing radiation interacts with DNA either by directly transferring energy to the biological material
or indirectly by creating reactive free radicals from the radiolysis of water. These interactions result in
damage to the DNA’s structure via broken covalent bonds. Linear energy transfer (LET) is an approach
to describe the spatial distribution of ionization and excitation produced by direct or indirect effects
of different types of radiation along a linear path [15]. Alpha (α) particles have high LET radiation
because they create dense ionizations and excitations in matter due to coulombic interactions with
atoms. Being a heavy charged particle, an α-particle will continuously slow down along its track with
minimal deflection. Through the process of slowing down, the interaction cross-section towards the
end of travel increases, resulting in increased LET, which is known as the Bragg Peak (Figure 2) [19,20].
Relative biological effectiveness (RBE) is the ratio of the dose of a reference radiation and the
dose of a test radiation that produces the same biological effect. Some of the most common biological
effect measurements are necrotic and apoptotic (programmed) cell death, DNA damage, chromosomal
aberrations and genetic mutations. The RBE of α-particles can range from 3.5 to 4 for cell killing or 6 to
12 for mutation, and be up to 10 for cell transformation [15]. As a comparison, the RBE for low LET
electrons and photons is 1.
An important biological endpoint is cell killing. Damage to cells can be classified as either
sub-lethal events or lethal events. Sub-lethal events are due to the accumulation of damage that has
the potential to be repaired, typically as a result of exposure to lower doses, and lethal events typically
result from irreparable damage due to exposure to higher doses [3]. The ability to repair these events
is seen as a shoulder on the cell survival curve and is characteristic of low LET radiation (Figure 3) [21].
A single event of high LET radiation can be lethal. The cell survival curve for a lethal event does not
have a shoulder, indicating the inability to repair [22].
The DNA double-strand break is the most biologically significant type of damage, which occurs
as a result of two single strand breaks in close proximity or a rupture of the double-strand at the
site of interaction [23]. Cell survival is highly dependent on the spatial distribution of double-strand
breaks [15]. Given the same dose, high LET radiation can create up to four times more double-strand
breaks of low LET radiation. Additionally, the formation of high LET double-strand breaks are more
complex compared to low LET in that they are less randomly distributed and form clustered DNA
damage to multiple base-pairs [19]. It has been widely accepted that high oxygen levels play a large
role in a cell’s sensitivity to ionizing radiation, and hence, tumor hypoxia is an established factor
in resistance to radiation therapy [24]. This is due to enhancement of free radical production by
the presence of oxygen. Free radical production occurs as a result of indirect action, or low LET
interactions. Since α-particles interact directly with the DNA, the level of oxygen becomes irrelevant;
hence, eliminating a major mechanism of resistance to therapy [3].
Molecules 2019, 24, 4314 5 of 48
Molecules 2019, 24 FOR PEER REVIEW  4 
observed in irradiated subjects were separated into one of two categories [3,6]: deterministic effects, 
which have a practical threshold absorption dose below which effects are negligible or not evident; 
and stochastic effects, where the relationship between dosage and severity of effect is either less 
evident or absent. 
Maintaining the integrity of many different types of macromolecular structures is important to 
cell viability and all cellular organic molecules are subject to damage by ionizing radiation. However, 
the genomic DNA molecules are considered to be the most critical targets for the biological effects of 
ionizing radiation because intact DNA is required for cellular replication and damaged but repaired 
DNA can result in the fixation of genetic mutations that can affect normal cellular function and 
viability [18]. Ionizing radiation interacts with DNA either by directly transferring energy to the 
biological material or indirectly by creating reactive free radicals from the radiolysis of water. These 
interactions result in damage to the DNA’s structure via broken covalent bonds. Linear energy 
transfer (LET) is an approach to describe the spatial distribution of ionization and excitation 
produced by direct or indirect effects of different types of radiation along a linear path [15]. Alpha 
(α) particles have high LET radiation because they create dense ionizations and excitations in matter 
due to coulombic interactions with atoms. Being a heavy charged particle, an α-particle will 
continuously slow down along its track with minimal deflection. Through the process of slowing 
down, the interaction cross-section towards the end of travel increases, resulting in increased LET, 
which is known as the Bragg Peak (Figure 2) [19,20].  
 
Figure 2. (A) Linear energy transfer (LET) versus distance in water traveled by typical α-particles
emitted by radionuclides in development for α-particle radioimmunotherapy: 225Ac (5.829 MeV)/213Bi
(8.375 MeV), 211At (5.867 MeV), 212Bi (6.08 MeV)/212Po (8.78 MeV), 223Ra (5.716 MeV). The range of the
α-particle and the position of the Bragg peaks are correlated with the initial energy of the α-particles.
LET of α-particles in water was calculated using stopping-power and range tables (continuous slowing
down approximation range) for electrons, protons and helium ions from the National Institute of
Standards and Technology (NIST). (B) The deposition of heavy ion energy as a function of penetrating
depth of (a) a pristine beam and (b) a modulated beam with widened stopping region (spread out
Bragg peaks). This figure and legend were reproduced from [19].
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Figure 3. Survival of a human kidney T-cell culture irradiated with ionizing particles of different kinds:
(1) particles with E = 2.5 MeV, LET = 165 keV/m; (2) particles with E = 27 MeV, LET = 25 keV/m;
(3) deuterons with E = 3.0 MeV, LET = 20 keV/m; (4) X-rays with E = 20 keV and LET = 6 keV/m;
(5) X-rays with E = 250 keV and LET = 2.5 keV/m; and (6) particles with E = 2.2 MeV, LET = 0.3 keV/m.
This figure and legend were reproduced from [21].
After exposure to radiation that results in DNA damage, the cell cycle can be stopped at cell-cycle
checkpoints which allow the cell to repair the damage via multiple repair mechanisms in order to
preserve genomic integrity [23]. In the case of irreparable damage, the cell will eventually undergo
cell death by apoptosis or necrosis. The two main repair mechanisms of double-strand breaks are
homologous recombination and non-homologous end joining. Homologous recombination occurs in
the late S and G2 phases of DNA synthesis where an intact DNA template is available, resulting in
more efficient and higher-fidelity repair. Non-homologous end joining occurs throughout the cell
cycle but is the only means of repair in G1 and early S phases. In this error prone repair method,
DNA ends are rejoined with no sister templates [22]. In this case, chromosomal aberrations can occur
as a result of recombining incorrect DNA ends; i.e., combining a loose end to some other molecule,
and the truncation of ends. If incorrect repair occurs prior to DNA replication, these errors can be
replicated in daughter DNA which can lead to mitotic cell death or can lead to the generation of
genomic mutations without cell death [22]. There is also the situation where double-strand breaks
are not repaired and the dividing cell enters mitosis, leading to mitotic catastrophe and eventual cell
death. A higher proportion of double-strand breaks remain un-rejoined after exposure to high LET
radiation [15]. When it comes to damage from high LET α-particles in close proximity to the cells being
irradiated, the main radiobiological effect is complex and irreparable DNA damage resulting in cell
death by either apoptosis or necrosis.
In the last few years, successful attempts have been made to explain the bystander effect [24,25].
The bystander effect is defined as a group of effects that are observed in cells that have not been directly
irradiated following the irradiation of other nearby cells. Two mechanisms were proposed. One is the
transfer of genomic instability through p53-mediated pathways, and the other suggests that irradiated
cells secrete cytokines or other factors that transit to other cells that are not irradiated and signal for
increased levels of intracellular reactive oxygen species [26]. One of the defined sub-classes of the
bystander effect is the “abscopal effect,” in which radiation treatment of a tumor propagates to tumors
outside the irradiated volume [26]. A more recent publication demonstrated an effect that might
explain the abscopal effect [27]. It was demonstrated that α-particle treatment of prostate cancer cells
generated an adaptive antitumoral immune response, as has been previously reported for other forms
of radiation. Combinations of bystander effects and the abscopal (likely immune) response in vivo
are potential mechanisms of the efficacy for tumors that are not venerable to the targeted α-emitter
radiotherapy in a patient with heterogeneous target expression.
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3. Alpha-Particle Emitting Radionuclides
Using radiation as a method of cancer therapy requires delivering the maximum dose to the
tumor while minimizing the dose to healthy tissues. Targeted radionuclide therapy is advantageous
in that it seeks molecular and functional targets within patient tumor sites [28]. Beta (β)-emitting
radionuclides (90Y, 131I, 177Lu and 186Re) are used for cancer-targeted therapy but have problems with
cross-fire irradiation of normal tissues due to their relatively long range in tissue, which is 0.5–12 mm.
In contrast, α-particles deposit higher energy over a much shorter range (40–90 µm), potentially
causing higher cytotoxicity to tumor cells while delivering a lower dose to normal, adjacent tissues [29].
Alpha (α)-emission is the process by which an unstable nucleus ejects a highly-energetic, heavy,
charged particle consisting of two protons and two neutrons. Alpha (α)-particles have a higher
LET (100 keV/µm) compared to β-particles (0.2 keV/µm) which results in a dense ionization track in
matter. The short range of α-emission provides specificity to the target cell population with a minimal
effect on surrounding normal cells, and the high LET leads to a high frequency of irreparable DNA
double-strand breaks [18]. This limits cytotoxic effects to within a small distance from the location
of decay. It has been estimated that only one cell traversal by an α-particle track is necessary to kill
a cell while, thousands of β-particle traversals are required for the same effect [30]. Because of the
long range of β-particles and the need of a high number of hits for cell killing, a large portion of the
dose deposited is outside of the intended target. In addition to treatment of solid tumors, the use of
α-particles for targeted treatment of circulating disease could be an improvement due to the potentially
reduced damage to normal tissues. Use of TAT has been considered for killing isolated cancer cells in
transit in the vascular and lymphatic systems, in regressing tumors by disruption of tumor capillary
networks and in treatment of micrometastatic foci [31]. In particular, TAT may be ideal for treatment of
solid metastases, as the short range will primarily kill tumor cells, with little deleterious impact on
surrounding normal tissue. Additionally, heterogeneity of target expression has been observed within
a given tumor or metastasis [32] and this is thought to be a mechanism of developing resistance to
targeted therapies; non-target expressing cells survive treatment and clonally expand into a resistant
population. In this case, α or β-emissions from a targeted cell will serve to kill surrounding untargeted
cells within the effective range, potentially reducing the development of resistance.
A number of factors need to be considered when choosing an α-emitting radionuclide for therapy.
These include proper nuclear characteristics, ease of radiochemical incorporation, specific activity,
synthesis yields, chemical and biological stability, availability and cost [29].
The physical half-life of the radionuclide should be long enough to allow for radiosynthesis
preparation and be compatible with the pharmacokinetics of tumor localization [33]. The decay
pathway of the α-emitter should be carefully analyzed. Due to the conservation of energy and linear
momentum, a daughter nuclide which subsequently decays by α-emission could detach from the
radioimmunoconjugate; see for example [34]. These free products could travel away and deposit
doses to healthy tissues. A decay chain that is long and complicated, having many different decay
types, could also present an issue dosimetrically, especially if the daughter products are metabolized
differently than the parent. A possible way to overcome this issue is to use 225Ac as an in vivo generator
in which the delivery system is designed to be internalized into the target cell where the toxic daughter
elements may detach from the targeting vector but remain trapped in the cell [35].
Another important nuclear characteristic is having a large number of α-emissions per decay.
The radiotoxicity associated with having multiple emissions could be high enough to kill a tumor
cell in a single decay. An accompanying gamma (γ) photon emission with energy suitable for in vivo
imaging is also beneficial for assisting with pharmacokinetic and dosimetric evaluations [33].
Another important element for radionuclide selection is availability. Alpha (α)-emitters are
produced either by cyclotron bombardment or by reactor irradiations, are incorporated into a generator
and are eluted from a parental source. Obtaining radionuclides in pure form with high specific activity
and large quantities is essential for adequate therapeutic evaluation. High specific activity is important
to avoid receptor saturation by the unlabeled targeting agent [36]. If membrane antigenic density is
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low, insufficient binding to tumor cells will occur [36]. Transportation of these radionuclides safely
and economically is also a key issue in selection.
While there are over 100α-emitting radionuclides, only several have been investigated in preclinical
and clinical studies. This is mostly due to radionuclides lacking nuclear properties, the absence of
viable chemistry, complicated decay chains and production and economic issues [37]. Therefore,
radionuclides meeting the criteria for therapeutic use have been limited to 225Ac, 211At, 212Bi, 213Bi,
212Pb, 223Ra, 224Ra, 149Tb and 227Th. The physical characteristics of these isotopes can be seen in Table 1.
Table 1. Physical characteristics of α-emitting radioisotopes investigated for clinical use.
Isotope Half-Life Max Energy Emissions Per Decay
225Ac 10.1 d 5.83 4 α, 2β-
211At 7.2 h 5.87 1 α, 1 EC
212Bi 1.01 h 6.09 1 α, 1β-
213Bi 45.6 min 5.87 1 α, 2β-
212Pb 10.6 h 6.09 1 α, 2β-
223Ra 11.4 d 5.87 4 α, 2β-
224Ra 3.6 d 8.8 5 α, 2 β-
149Tb 4.1 h 3.96 1 α, 1 β+
227Th 18.7 d 6.04 5 α, 2β-
The first α-emitter to be used in human clinical trials for therapy was 213Bi in 1997, when it was
labeled to the anti-leukemia antibody HuM195 [38]. 213Bi is available through generator based 225Ac
and decays with a 45.6 min half-life by emission of one α (8.37 MeV) and two β-particles. The generator
is produced at Oak Ridge National Laboratory in the US and at the Institute for Transuranium Elements
in Karlsruhe Europe. In the decay of 213Bi, there is an emission of a 440 keV isomeric γ, which is
beneficial for imaging studies.
211At decays with a half-life of 7.2 h and emits two α-particles through a split decay pathway with
energies of 5.87 and 7.45 MeV. One path is to 207Bi by α-emission followed by electron capture to 207Pb
and the other is by electron capture to 211Po followed byα-emission to 207Pb. An advantage of this decay
path is that 211Po emits 77–92 keV characteristic X-rays which can be used for imaging [37]. The main
disadvantages are availability and purity. Conventionally, the production of 211At requires α-particle
cyclotrons, which are only available in a few places worldwide, to produce the 209Bi(α,2n)211At reaction
with minimal 210At contamination [39]. Astatine has significant metallic characteristics that lead to
complications in standard antibody labeling and results in a rapid release of free 211At [37,40,41].
To resolve this problem, approaches have been developed by several research groups based on
small linker molecules that create an aryl carbon–astatine bond involving an astatodemetallation
reaction using tin, silicon or mercury precursors [42]. Other alternative methods for astatination,
e.g., boron-astatine, rhodium-astatine or nanoparticle encapsulation, are also being pursued [43].
225Ac is a radiometal with a half-life of 10.1 days and produces six radionuclide daughters in
the decay path to stable 209Bi. For each decay event of 225Ac, there are successively, four α and two
β emissions with high energy (α 8.38 MeV, β 1.42 MeV). In the decay of 225Ac and its daughters
there are several isomeric γ emissions with energy suitable for imaging studies. The relatively long
half-life allows for a centralized production site that can ship 225Ac to users [44]. The main method for
generating 225Ac for clinical studies is through the decay of 229Th which originates from 233U. In the
world there are three main sources of 229Th: Oak Ridge National Laboratory (USA), The Institute of
Physics and Power Engineering (Russia) and The Institute for Transuranium Elements (Germany).
The quantities produced are not enough for a global application of 225Ac. To keep up with the increasing
demand for 225Ac for clinical applications, it has been found that large scale quantities can be produced
through high-energy proton irradiation of 232Th [45,46]. To address the shortage, the US Department
of Energy formed a Tri-lab collaboration of Los Alamos (LANL), Brookhaven (BNL) and Oak Ridge
(ORNL) National Laboratories with the goal of developing an alternative route for production of Ac [47].
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Another limitation for this radionuclide has been with the radiochemical stability of the attachment to
immunoconjugate. McDevitt et al. [34], state that the instability of these attachments is due to the high
classical recoil energy (100–200 keV) of the daughter product which breaks the molecular bonds of the
chelator. Significant advances have been made in developing chelators that form thermodynamically
stable and kinetically inert complexes with 225Ac. Khabibullin et al., recently calculated the chelation
stability of 225Ac and daughters in the 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)
chelator [48].
As one potentially abundant starting material, 212Bi (1.01 h half-life) can be obtained from 228Th
and decays via a branched pathway to 208Tl (36% α) and 212Po (64% β); then, both decay to stable
208Pb [33]. However, 212Bi has several disadvantages that potentially limit its use. First, its short
half-life can be problematic if the production and shipping processes are lengthy. This issue can
be solved by using 224Ra as a generator to locally produce 212Bi. Another complication is the high
energy γ emission (2.6 MeV) which requires a considerable amount of shielding to minimize exposure.
This, along with the short half-life, makes shipping difficult, resulting in an availability problem.
223Ra is found naturally in trace amounts following the decay of 235U, but it is mainly produced
artificially by the decay of 227Th (T1/2 = 18.7 days), which is produced from 227Ac (T1/2 = 21.77 years).
Since 227Ac is found only in traces in uranium and thorium ores, it is mainly synthesized by 226Ra
(T1/2 = 1600 years) irradiation in a nuclear reactor [49]. 223Ra has a half-life of 11.4 days and emits
four α-particles, two β-particles and γ rays on the path to stable 207Pb [34]. While the emission of
four α-particles is advantageous for tumor toxicity, 219Rn in gaseous form is also emitted, which can
redistribute in the body and dose non-targeted cells. See Figure 3 for comparable energies of α-particles.
The major challenge using 223Ra is finding a suitable ligand for in vivo sequestration. However,
similarly to cations of the alkaline earth elements, radium has natural bone-seeking properties without
the need for a carrier agent. As radium mimics calcium, when 223Ra dichloride (Xofigo®) is injected
intravenously, it forms complexes with the bone mineral hydroxyapatite at areas of increased metabolic
bone activity, such as bone metastases, thereby exerting a highly localized antitumoral effect [7].
In addition, the 223Ra daughter isotopes are also retained in the bone matrix [50].
Thanks to this characteristic, 223Ra dichloride (223RaCl2) has demonstrated improvement in overall
survival for the treatment of bone metastases in castration-resistant prostate cancer and has received
FDA approval for this application [34], making it the first FDA approved TAT.
227Th can be produced continuously from 227Ac and decays with a half-life of 18.7 days to
223Ra [51]. The long half-life is beneficial for radiolabeling and targeting. 227Th also decays with
accompanying γ emissions of 236 keV and 50 keV, which can be used for imaging but are low enough
to avoid the need for patient shielding.
212Pb has a 10.6 h half-life and is produced either from the decay chain of 228Th or by the 224Ra
generator [39]. Because of its long half-life and the fact that 212Pb is a β-emitter that decays to 212Bi,
one approach has been to use this radionuclide as an in vivo generator to compensate for the short
half-life of 212Bi [52]. 212Pb can deliver over ten times the dose per unit of administered activity
compared to 212Bi or 213Bi [53]. The major issue with 212Pb is the electron capture and auger electron
emissions which can cause significant recoil of the 212Bi daughter [54]. The free 212Pb has been
shown to cause severe bone marrow toxicity [55], while the free Bi has shown to cause kidney toxicity.
By co-injecting DTPA or EDTA chelating agents, rapid release of free 212Bi can be achieved [56].
4. Targeting Moieties
In the burgeoning field of targeted radiopharmaceuticals, there is no universal answer to the
question: what is the best targeting molecule? Rather, the abundance of target molecule classifications
allow for a more customized approach to developing TATs. Globally, the requirements of a targeting
ligand include the ability to concentrate at and bind to extracellular targets and the availability
of chemical functional groups amenable to the attachment of linkers and chelators. A balance of
many other factors like off-target binding, biodistribution and pharmacokinetics (particularly with
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respect to the decaying half-life of the chosen radionuclide) are all critical factors for the selection
of a proper targeting ligand. Recently, small molecules, peptides, antibodies, antibody fragments
and even some passive targeting strategies have been investigated to deliver radioisotope payloads.
See Tables 2 and 3 for examples of TAT conjugates that have been studied in the pre-clinical and clinical
environments. This section will explore the advantages and challenges of the aforementioned targeting
ligand categories.
4.1. Small Molecules
An advantage of using low molecular weight ligands as targeting moieties for α-therapy include
rapid penetration into the tumor and rapid clearance of unbound conjugates from circulation; thus,
reducing toxicity. Internalizing ligands are particularly beneficial for 225Ac’s application in order
to harness the multiple α-particles emitted in its decay chain. A successful example of using small
molecules in TAT is 225Ac-PSMA-617 for the therapy of metastatic, castration-resistant prostate
cancer [57,58]. The favorable pharmacokinetics properties of the PSMA-617 small molecule include its
fast tumor uptake, high internalization rate, extended tumor retention and rapid clearance of unbound
ligand [58]. These features make the molecule highly desirable for labeling with an α-emitter with a
half-life of several days and multiple α-emissions in its decay chain, like 225Ac. The first report of the
significant therapeutic efficacy of 225Ac-PSMA-617 involved two patients with late-stage, metastatic,
castration-resistant prostate cancer (mCRPC) and complete remissions [59]. Additional clinical studies
have further revealed the remarkable anti-tumor activity and the promising duration of tumor-control
of treatment with 225Ac-PSMA-617 [6,59,60]. These studies have further demonstrated the significant
potential of TAT (Table 3, Figure 1). Xerostomia (dry mouth syndrome) was the main side effect,
indicating that further modifications in clinical trial design might be necessary to further enhance the
therapeutic range.
4.2. Peptides
Peptides are oligomers of amino acids that may sometimes exhibit secondary structure; they may
have branched or linear frameworks, and may be composed of varying amounts of non-canonical
monomers. The polypeptide chains of peptides can have anywhere from 2 to 70 amino acids but
more typical examples of targeting peptides are made of less than 10–15 amino acids (1000–1500 MW).
Owing to this molecular weight and their capacity to be synthesized and modified with conventional
organic synthesis techniques, peptides have long been utilized as targeting agents for radionuclide
therapies and diagnostic applications.
Since the 1980s, analogs of the endogenous peptide hormone somatostatin have been developed as
therapeutics for neuroendocrine disorders [61]. The FDA approved octreotide (OC, Figure 4), the cyclic
octapeptide, upon which much of the early peptide receptor radionuclide therapy (PRRT) was based.
Chelating molecules attached and various radionuclides for β and α-emission therapies have been
reported. Figure 4 details the structure of OC and two of its commonly-used PRRT ligand analogs,
DOTATOC and DOTATATE.
Nephrotoxicity is often one of the highest concerns in PRRT due to tubular reabsorption of the
labeled peptide after glomerular filtration [62]. Seventy-four human patients were followed (>1 year)
after PRRT with the β-emitter 177Lu-Octreotate. Renal function was monitored by accessing glomerular
filtration rate (GFR). Somewhat surprisingly, renal impairment was minimal, with only 43% of patients
experiencing a decrease in GFR (<2 mL/min/m2 per year) and 11 patients actually saw increased
GFR (>10 mL/min/m2 per year) [63]. The first published account of the α-emitter 213Bi in an OC
analog (DOTATOC, Figure 4) was reported in 2006. The radio-peptide ligand was shown to retain its
affinity for the somatostatin receptor and inhibited tumor growth in a somatostatin receptor-positive
rat pancreatic tumor model (CA20948) [64]. Importantly, the study followed major organ toxicities in
rodents. Little to no nephrotoxicity was observed at the various administered activities (13–22.2 Mbq).
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More recently, even tumors that had become radioresistant toβ-therapy (90Y and 177Lu–DOTATOC)
responded to 213Bi–DOTATOC in a clinical model of eight human patients [65]. The treatment for each
patient was individualized according to each particular disease state and each patient had substantially
positive outcomes in terms of tumor regression and survival. Critically, the acute hematological
toxicity normally associated with the analogous β-therapies was only moderate. This limited report
suggested only a mild reduction in acute renal function. No other major acute toxicities were reported.
This first-in-human report of this peptide-targeted alpha therapeutic may lay the ground work for
future human TAT using peptide-targeted systems.Molecules 2019, 24 FOR PEER REVIEW  11 
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It has been the common supposition that TAT would work well for small, disseminated tumors
but not as well for large, solid tumors. Recently, DOTATATE (Figure 4) was labeled with 213Bi
and used to investigate efficacy differences in tumor size among two tumor models, rat pancreatic
(CA20948) and human small cell carcinoma (H69) with each containing a small (50 mm3) and large
(200 mm3) tumor group [66]. Both tumor lines maintained high expression of SSTR2 and all tumor
groups saw delayed tumor growth and higher survival over controls. Three mice from the smaller
tumor groups were effectively put into remission through the end of the study. This report has
implications for TAT in regard to tumor receptor heterogeneity, tumor size and perfusion. More
recently, α-emitting radionuclides have been conjugated to melanocortin 1 receptor targeting peptides
and efficacy determined in the pre-clinical treatment of mouse xenograft models of cutaneous and
uveal melanomas [67–69].
4.3. Antibodies
Full length immunoglobulins (IgGs) are typically in the 150 kDa molecular weight range, and have
been proven to hav high binding affinity and pecificity to a broad range of extracellular receptor .
Developments in hybridoma cell line technology have op ned the door to the production of m oclonal
antibodies (mAbs) which ca be labeled with chelating mol cules, to which radionuclid s can be added.
This approach to spe ifically deliv r io izing radiation paylo ds is termed radioimmunotherapy (RIT).
While many of the examples here will involve radioactive payloads directly conjugated to the protein,
antibodies have also been employed to target macromolecular payloads, such as nanoparticles and
liposomes, to cellular targets [70–72].
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A research group based in the Memorial Sloan-Kettering Cancer Center (MSKCC) has reported
several accounts of their work labeling trastuzumab with actinium 225. This mAb is the well-known
and FDA approved HER2/ERRB2-targeting agent. Initially, they showed through a three cell line,
spheroid in vitro model that their α-RIT scheme could penetrate spheroids, retard growth and prevent
regrowth of colonies in a dose dependent manner [73]. While a promising start, this work underscored
the importance of target expression and also suggested challenges of RIT due to extravasation of
targeting agents in normal tissues and toxicities of released/free decaying daughter products [74,75].
The MSKCC Scheinberg group’s work eventually led to the first clinical trial of an actinium 225
chelated targeting antibody (Clinical Trials.gov Identifier: NCT00672165). This α-RIT scheme utilized
the previously-explored humanized anti CD33 antibody, limtuzumab, to target acute myeloid leukemia
cells. Subsequently, that preliminary work led to the birth of Actinium Pharmaceuticals, Inc. and a
portfolio of targeted 225Ac conjugated constructs in both preclinical and clinical pipelines.
Astatine-211 has also been utilized for α-RIT. In 2013, Orozco and coworkers coupled a decaborate
cage structure (B10, Figure 5) with 211At to anti-CD45 antibody in an attempt to target acute myeloid
leukemia [76]. More recently Green and coworkers reported an example using anti-CD20 mAb
conjugated with a 211At with a similar B10 labeling scheme [77]. This study sought to eliminate minimal
residual disease (MRD) in a mantle cell lymphoma animal model. Their remarkable results showed
70% eradication of the MRD in animals bearing a disseminated model. However, the subcutaneous
lymphoma xenograft group treated with the same agents only saw prolonged survival (two to
three-fold) without any cured animals. This study is clear evidence of the need for tumor perfusion of
the TAT.
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4.4. Antibody Fragments
A limitation of full-size IgGs is their typical 1–3 week serum stability. While this kind of
circulation may be advantageous for certain therapeutic applications, for radioimmunotherapy (RIT) it
presents a serious liability. Excess antibody can continue to circulate, lowering the tumor-to-nontumor
(T/NT) ratio, particularly with respect to the tumor-to-blood (T/B) ratio. Finally, high levels of
continuously-circulating α-emitters result in hematological toxicities, as well as extravasation in
normal tissues.
In attempts to shorten the long plasma half-life of full-length antibodies, many groups have sought
to reduce the sizes of the mAbs while retaining their remarkable binding characteristics. To those ends,
antibodies have been cleaved into smaller sections through enzymatic digestion and also engineered
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ab initio [78,79]. For comparison, the engineered antibody fragments of diabodies (Db) and minibodies
(Mb) have typical circulating half-lives of 2–5 and 5–12 h, respectively, while the circulating half-life
of full-length IgGs is more typically 1–3 weeks. Monovalent and bivalent affibodies (7 and 15 kDa
respectively) have been developed with targeting specificity to HER-2 and they have plasma half-lives
of roughly 45 min [80]. The science of antibodies is ever progressing and new classes are still being
observed in nature; nanobodies (13–14 kDa) are heavy chain-only antibodies, that have been isolated
from Camelidae and have lately been conjugated with theranostic radionuclides [81]. These new
categories of targeting constructs are adding to the growing body of evidence that there may be a
so-called ‘Goldilocks’ zone in terms of the size of targeting constructs.
4.5. Passive Targeting
Another strategy often employed for TAT is based on the natural selective uptake and accumulation
of certain elements. For instance, the actively restructuring environment of osteoblastic bone metastases
is conducive to calcium accumulation in the form of hydroxyapatite. Due to the resemblance of
radium-223 to calcium, it can act as a surrogate and be incorporated into the rapidly-growing
matrix [7,29]. Indeed, the recent approval of 223Ra dichloride therapies for metastatic castrate-resistant
prostate cancer has been followed in patients for over twelve months with moderately successful
outcomes [82]. Other studies have looked to 223Ra dichloride for the treatment of the bone metastases
from hormone-refractory breast cancer [83,84].
The enhanced permeability and retention (EPR) effect is often regarded as a rationale for the
passive targeting of large macromolecules like nanoparticles and liposomes. This accumulation
of macromolecules through the leaky vasculature of quickly-dividing tumor cells also provides
the opportunity to incorporate multiple radionuclides into the framework of a targeting molecule.
Additionally, it has been proposed that nanoparticles or liposomes could be used to sequester decaying
daughter products that would otherwise be released to freely circulate in the blood because of damage
to molecular bonds due to α-decay or metabolism of the radiopharmaceutical [85,86].
5. Chelation/Attachment
5.1. Radiosynthesis
The recent approval of 223RaCl2 has reinvigorated research into TAT development [87]. Several
α-particle-emitting radionuclides have been described in the literature, and these include 211At,
212/213Bi, 212Pb and 225Ac [44,88,89]. With the exception of 211At [41,42,90], all are radiometals that
require a bifunctional chelator for the attachment of the therapeutic radioisotope to the targeting
moiety. The chemistries of 212/213Bi and 212Pb have been covered extensively elsewhere [91–94].
The radiochemistry of radium has recently been reviewed [95]. This section will cover recent advances
in 225Ac chelation chemistry that have occurred since the publication of the excellent review by
Scheinberg and McDevitt in 2011 [96].
225Ac, whose decay chain was not finally resolved until the middle of the 20th century is one of 29
radioactive isotopes of actinium, which is the first element of the actinide series [97]. Although the lack
of non-radioactive actinium isotopes has hindered the exploration of 225Ac chemistry, the pioneering
work of Seaborg and others has provided an important understanding of the basic reaction chemistry
of this element [97–99]. Actinium chemistry has been observed to closely follow that of lanthanum
chemistry, since both exist as trivalent ions in solution. These observations have led to the belief that
La3+ can be an important non-radioactive surrogate for Ac3+, with the caveat that the differences in
ionic radii must be considered carefully [100].
Despite the relatively limited knowledge of actinium chemistry, the medical community has
seized upon its therapeutic potential in TAT. Using lanthanide chemistry as a guide, many attempts
to attach this radioisotope to targeting molecules have been reported with a variety of acyclic
and cyclic ligands that would effectively chelate this radioisotope [101–106]. To date, however,
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only 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) has found widespread acceptance
as an 225Ac chelator in both preclinical and clinical applications [96], despite the low radiochemical
yields and specific activities that have been reported [73,104,107]. Maguire et al. have described an
improved, one-step 225Ac radiolabeling procedure of monoclonal antibodies that resulted in a 10-fold
increase in radiolabeling yield and a 30-fold increase in specific activity [108]. The authors concluded
that the improvements in yield and specific activity resulted from greater control over the DOTA–mAb
conjugation reaction and the improved chelation of 225Ac during radiosynthesis. Additionally, the new
procedure did not alter antibody activity or therapeutic efficacy in vivo, which further suggests the
usefulness of this strategy. More recently, Poty et al. reported a single-step click chemistry approach to
225Ac-radioimmunoconjugate synthesis [109]. The click approach generated superior radiochemical
yields compared to the standard two-step strategy, suitable specific activities, good in vitro stability
and excellent biodistribution profiles. The authors proposed that said novel click strategy could be
applied when the targeting vector is unstable under the conditions used for the standard method.
Despite improving the radiochemical yield and specific activity of 225Ac radiopharmaceuticals,
important challenges, which include minimizing the detrimental effects of recoil energy and effectively
sequestering the cytotoxic daughter products 221Fr and 213Bi after 225Ac decay, remain to be overcome.
While several reports have described cellular internalization as an effective method of sequestering
225Ac and its daughter products [35], scientists are increasingly turning to nanotechnology to resolve
this issue, and a variety of nanoparticles, including liposomes and carbon-based nanoparticles,
have been explored [96,110–115]. Recent reports have demonstrated that LaPO4 nanoparticles hold
promise as safe and effective nanocarriers for 225Ac [71]. In these studies, the authors synthesized
LaPO4 (monazite) nanoparticles doped with 225Ac. These particles were prepared with functionalized
surfaces that facilitated the attachment of 201B mAb, which targets murine thrombomodulin on lung
epithelium. Upon in vivo injection, targeted particles accumulated rapidly in the lung through specific
interactions between the 201B mAb and its antigen. Moreover, retention of 225Ac and half of the 221Fr
and 213Bi daughter nuclei within the particles demonstrated the potential for trapping radionuclides
after high energy emissions. McLaughlin et al. improved upon this work by examining 225Ac-doped
LaPO4 nanoparticles that were encapsulated by GdPO4 and Au shells [86]. These particles had an
average diameter of 27 nm, and were easily conjugated to the 201b mAb using standard bioconjugation
techniques. Biodistribution and small animal single-photon emission computed tomography (SPECT)
studies revealed the specific targeting of murine thrombomodulin within the lung epithelium that
was reduced upon the administration of non-radioactive 201b mAb. Interestingly, the multi-layered
nanoparticle design seemed to increase the retention of 225Ac, 221Fr and 213Bi within the particle,
which reduced the radiation dose experienced by the kidney. Approximately four and five-fold
reductions were observed at 1 and 24 h post-injection, respectively. These data demonstrate that
multi-functional, layered nanoparticles have the potential to deliver and retain 225Ac and its daughter
radionuclides at the target site, while minimizing off-target toxicities that can occur from errant
daughter products in the 225Ac decay chain.
5.2. Linkers/Rational Design
The most utilized chelating molecules for targeted radionuclide therapies using biological
molecules are 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and diethylene triamine
pentaacetic acid (DTPA), and their related analogs (Figure 5). Depending on the how the compound is
linked to the targeting ligand, these organic structures feature 3 or 4 carboxylates that are negatively
charged at physiological pH, and along with the lone pair electrons from each of the 3 or 4 nitrogens,
they can coordinate metal ions like α and β-emitting radionuclides. Often, these chelating molecules
are linked to the targeting molecule by forming a new amide bond between an amine on the targeting
molecule and a carboxylate on the DOTA/DTPA. This strategy is particularly advantageous in the case
of peptide synthesis since the reaction, characterization and purification of the linker addition can be
part of the overall synthesis of the targeting ligand.
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When DOTA or DTPA are linked to proteins like antibodies, amide bonds are typically created
between a primary amine of surface-exposed lysine residue and an activated carboxylate on the DOTA
or DTPA (Figure 6). Another widespread chemistry available to link protein lysines with DOTA or
DTPA is through an isothiocyanate which yields a stable thiourea (Figure 6) [53,116]. While these
newly formed amide bonds create the same covalent structure as the peptide-synthesized version,
there are important distinctions. In the stochastic reaction of any accessible lysine, many different
combinations are possible, and there is little to no control over the regioselectivity of the conjugation.
It is unlikely, but possible, that targeting ligands could block or hinder the antigen-binding sites on
the antibody.
Molecules 2019, 24 FOR PEER REVIEW 15 
different combinations are possible, nd here is little to no c ntr l over the regioselectivity of the 
conjugation. It is unlikely, but possible, that targeting ligands could block or hinder the 
Figure 6. Common conjugation chemistries used to functionalize biomolecules. Countless other 
schemes have been well characterized and the reader is directed to Bioconjugates Techniques for a 
review and protocols [117]. 
The importance of site-specific modifications to biologic targeting motifs is only recently 
becoming clear. In a 2014 paper from UCLA [118], diabodies (Dbs) were conjugated both site-
specifically through reduced cysteines and non-specifically through accessible lysine ε-amines to 
DOTA chelators. While the tumor-to-blood ratio of the specifically labeled protein was moderately 
higher than the more heterogeneous product, the more striking result was the renal and hepatic 
distribution. Kidney uptake levels were almost doubled for the cysteine-labeled Db, and liver uptake 
levels were reduced for the non-specific amine-labeled Dbs.  
Other important research regarding linkers has uncovered different methods to reduce kidney 
toxicity, via the renal reabsorption of radiolabeled peptides and antibody fragments, as they are 
filtered by the glomerulus. By taking advantage of renal brush border enzymes, the radionuclide can 
be cleaved from targeting ligand and excreted. By engineering an antibody fragment with a C-
terminal lysine, and subsequently modifying the ε-amine with DOTA:indium-111, Li and coworkers 
demonstrated a 50%-60% reduction in the kidney-uptake of the radionuclide [119]. More recently, a 
Japanese group probed the brush border enzymes to understand more about their specificity and 
they were able to pinpoint a glycine-tyrosine linkage that specifically cleaved a radio-iodinated 
benzoate derivative from an antibody Fab fragment [120]. Presumably, a similar strategy could be 
used for the α-emitting halogen, 211At.  
Polyethylene glycol (PEG) linkers are made of repeating –CH2CH2O– monomers and are 
commonly employed by chemists to alter biodistribution and pharmacokinetics. PEGs can be 
prepared in two categories, polymeric and discrete oligomers. Bifunctionalized versions of these 
polymers can link targeting molecules with the chelating agent or just add bulk/solubility to lower 
molecular weight entities. Researchers wishing to reduce immunologic response to nanoparticles 
have been known to decorate their macromolecules with PEG [70], as was the case with McLaughlin 
and coworkers with PEG12 linker used to link 225Ac containing nanoparticles to mAb [86]. 
6. Radiation Dosimetry
Dosimetry provides means for evaluating the efficacy of a radiation therapy modality [3]. 
Because the goal is to a deliver high dose to tumor cells with a minimal dose to normal tissues, it is 
of great importance to quantify accurately where, when and how a dose is being deposited. The 
Medical Internal Radiation Dose Committee (MIRD) developed an approach to determine the 
average absorbed dose from internal radionuclides [121]. The absorbed dose method accounts for 
low LET radiation where thousands of statistically independent deposition events across a cell are 
required to induce a biological effect [3]. With respect to an α-particle’s interactions, the averaged 
Figure 6. Common conjugation chemistries used to functionalize biomolecules. Countless other
schemes have been well characterized and the reader is directed to Bioconjugates Techniques for a
review and protocols [117].
The importance of site-specific modifications to biologic targeting motifs is only recently becoming
clear. In a 2014 paper from UCLA [118], diabodies (Dbs) were conjugated both site-specifically
through reduced cysteines and non-specifically through accessible lysine ε-amines to DOTA chelators.
While the tumor-to-blood ratio of the specifically labeled protein was moderately higher than the more
heterogeneous product, the more striking result was the renal and hepatic distribution. Kidney uptake
levels were almost doubled for the cysteine-labeled Db, and liver uptake levels were reduced for the
non-specific amine-labeled Dbs.
Other important research regarding linkers has uncovered different methods to reduce kidney
toxicity, via the renal reabsorption of radiolabeled peptides and antibody fragments, as they are filtered
by the glomerulus. By taking advantage of renal brush border enzymes, the radionuclide can be cleaved
from targeting ligand and excreted. By engineering an antibody fragment with a C-terminal lysine,
and subsequently modifying the ε-amine with DOTA:indium-111, Li and coworkers demonstrated a
50%-60% reduction in the kidney-uptake of the radionuclide [119]. More recently, a Japanese group
probed the brush border enzymes to understand more about their specificity and they were able to
pinpoint a glycine-tyrosine linkage that specifically cleaved a radio-iodinated benzoate derivative
from an antibody Fab fragment [120]. Presumably, a similar strategy could be used for the α-emitting
halogen, 211At.
Polyethylene glycol (PEG) linkers are made of repeating –CH2CH2O– monomers and are commonly
employed by chemists to alter biodistribution and pharmacokinetics. PEGs can be prepared in two
categories, polymeric and discrete oligomers. Bifunctionalized versions of these polymers can link
targeting molecules with the chelating agent or just add bulk/solubility to lower molecular weight
entities. Researchers wishing to reduce immunologic response to nanoparticles have been known to
decorate their macromolecules with PEG [70], as was the case with McLaughlin and coworkers with
PEG12 linker used to link 225Ac containing nanoparticles to mAb [86].
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6. Radiation Dosimetry
Dosimetry provides means for evaluating the efficacy of a radiation therapy modality [3]. Because
the goal is to a deliver high dose to tumor cells with a minimal dose to normal tissues, it is of great
importance to quantify accurately where, when and how a dose is being deposited. The Medical
Internal Radiation Dose Committee (MIRD) developed an approach to determine the average absorbed
dose from internal radionuclides [121]. The absorbed dose method accounts for low LET radiation
where thousands of statistically independent deposition events across a cell are required to induce a
biological effect [3]. With respect to an α-particle’s interactions, the averaged absorbed dose will fail to
characterize biological outcome. Because the α-particle range is only a few cell lengths, some cell nuclei
will receive multiple traversals while others will receive zero traversals. Additionally, the location
of the α-particle track will determine the energy absorption by the cell. These factors result in large
statistical variability of energy deposition and stochastic effects become important. To account for
those effects, Roeske developed a microdosimetric methodology based on the mean dose to target cells,
probability distribution of specific energy absorbed by target cells, and the fraction of cells receiving
zero hits [122]. Kellerer and Chmelevsky described the requirement that microdosimetry must be
used when the relative deviation of local dose is greater than 20% [122]. Following this criterion,
microdosimetric techniques are more important in analyzing non targeted cells where the local average
dose is small, resulting in larger variations than targeted cells.
In most cases, the activity level and mean absorbed doses to the target are large, resulting in a
low expected stochastic deviation, and therefore, there is no need to use microdosimetric techniques.
The MIRD Pamphlet No. 22: Radiobiology and Dosimetry of Alpha-Particle Emitters for Targeted
Radionuclide Therapy recommends using the conventional MIRD formalism [3]. The mean absorbed
dose to the target region, rT, from a source region, rS, due to a particular emission type, x, over a dose
integration period, TD, is given by:








where Ã(rS, TD) is the total number of nuclear transitions in the target region; ∆xi is the mean energy
emitted per disintegration for the i-th emission of type x; ϕ
(
rT ← rS; Exi
)
is the fraction of energy
emitted per nuclear transition in the source region that is absorbed in the target region by the i-th
emission of type x that is emitted with initial energy E; and M(rT) is the mass of the target region.
The total number of nuclear transitions is determined by measuring activity levels in tissue samples at
several points in time post administration. The activity levels plotted against time gives a time-activity
curve which is integrated to obtain the total number of nuclear transitions. The mean energy emitted
per emission ∆i is a physical property of the radionuclide and can be obtained from nuclear decay
tables. The absorbed fraction for each decay type is dependent on the reference phantom geometry
and obtained through Monte Carlo calculation. The dose contribution from each emission type is then
weighted by its relative biological effectiveness, and then summed:
DRBE(rT, TD) = RBEαDα(rT, TD) + RBEeDe(rT, TD) + RBEphDph(rT, TD) (2)
Several assumptions are made when using this formalism of dose calculation. It is assumed
that the activity is uniformly distributed in the organ and that α-energy deposition is also uniformly
distributed in the organ. It is also assumed that dose from both α and β-emissions are locally deposited.
The calculation of the absorbed fractions is based on idealized phantoms that have standard geometries
which cannot account for the individual anatomy of a patient. It is also important to note that
radioactive daughters are not taken into account. Therefore, daughter decays must also be calculated,
as well as accounting for daughters’ biodistribution. The formalism was developed as an adequate
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method for the dosimetry of internal radionuclides used for diagnostic purposes and lacks the accuracy
needed for therapeutic applications.
As a first method to improve on the original MIRD formalism, phantoms were developed to better
match the standard human anatomy. For example, Christy and Eckerman developed phantoms that
represented a male, a female and children [123]. Later, as computational power increased, voxelized
phantoms like VoxelMan were created based off 3D imaging [124]. MIRD Pamphlet No. 17 describes a
method to extend the S value formalism to the voxel level to account for nonuniform distributions
of activity [125]. The most extensive software that has adapted the MIRD S factors is OLINDA/EXM,
which has calculated an internal dose for over 200 radionuclides, including α-emitters, in 10 different
phantoms [126].
The voxel S method is still a model-based approach to dosimetry. There is much less tolerance
for inaccuracies in therapeutic applications, which calls upon the need for patient-specific dosimetry.
In order to accomplish this, the patient’s own anatomy, obtained from CT, is used in combination with
SPECT imaging to obtain 3D spatial distribution of activity. It is advantageous for the α-emitting
radionuclide to also haveγ photon emission as it decays so that SPECT imaging can provide information
about regional uptake. The method to calculate a 3D, imaged-based dose is as follows [127]. Serial
SPECT studies taken over time post administration of the radiopharmaceutical can determine the
pharmacokinetic variations within an organ on the voxel level. The SPECT/CT images are registered
together and integrated voxel by voxel over time to obtain the 3D, time-integrated activity. The CT
provides a map of tissue electron density for each voxel, which is necessary for dosage calculations.
A Monte Carlo package is then employed using the activity distribution as the source definition
and energy deposition is tallied in each voxel. Several software packages are available for 3D,
patient-specific dosimetry, including MCID [128], OEDIPE [129] and SCMS [130] which are based
on MCNP, 3D-RD [131] and DOSIMG [132] which are based on EGS [133], RAYDOSE [134] and
RAPID [135] which are based on GEANT4 [136], and DPM [137], which is not a public domain
code. Both MCNP and GEANT4 can simulate α-particles, while EGS can only transport photons
and electrons.
While imaging-based dosimetry can account for non-uniformity and calculate dose at the voxel
level, it is still a macroscopic quantity. The spatial resolution of current SPECT imaging ranges from 5
to 25 mm [31]. These dimensions are much larger than the 40–90 µm range of an α-particle. This results
in the stochastic variations due to α-particle energy depositions not being taken into account and the
voxel dose could be misleading. For α-particles, the ideal dosimetric targets are isolated cancer cells in
transit in the vascular and lymphatic systems, micro-metastases and tumor capillary networks [31].
The only way to study the dosimetry of α-particles on a small scale is pre-clinically. These have been
limited to in vitro measurements and microdosimetric Monte Carlo models. However, recently, several
groups have developed alpha cameras, such as the Ionizing-Radiation Quantum Imaging Detector,
which provides images of the ex vivo activity distribution with a spatial resolution on the order of tens
of microns µm [138,139]. Monte Carlo methods can then be employed to calculate the dose absorbed
on that scale. This is viewed as an important advancement in alpha dosimetry because no further
modeling was needed to obtain the spatial and temporal activity distribution.
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Table 2. Preclinical targeted alpha-particle therapy (TAT) studies.
Isotope Study Molecular Target Targeting Moiety Drug(s) & Route Cancer Type & Animal Model Key Results Ref
225Ac Efficacy, toxicity PSMA, CD19 J591 & B4 mAbs 225Ac–DOTA–J591, 225Ac-B4, i.v.
Human LNCaP prostate s.c.
xenografts & disseminated Daudi
lymphoma in male nude mice.
Both effective
without toxicity. [35]
225Ac Efficacy, toxicity HER-2/neu Trastuzumab 225Ac–DOTA–trastuzumab, i.p.
SKOV3 human ovarian cancer s.c.
xenografts in female nude mice. Effective with no toxicity. [148]
225Ac PK, RD, toxicity CD33 HuM195 Ab 225Ac–DOTA–HuM195, i.v.
Cynomolgus monkey leukemia
(does not express the human
CD33 target).






toxicity Ganglioside GD2 3F8 Ab
225Ac–DOTA–3F8, i.v.
NMB-7 human neuroblastoma
xenografts in nude mice (BD),
meningeal carcinomatosis













225Ac and 177Lu–DOTATOC, i.v.
AR42J rat pancreatic exocrine s.c.
xenografts in nude mice.
225Ac-TAT had greater
efficacy relative to






efficacy, toxicity HER-2/neu 7.16.4 mAb
225Ac, 213Bi and 90Y-7.16.4, i.v.
neu-N transgenic mouse model
with rat HER-2/neu expression
and spontaneous lung metastases
& NT2.5 mouse mammary fat pad
xenografts with rat HER-2/neu.
225Ac-TAT had greater
efficacy but with renal










carcinomatosis in SCID mice.
225Ac-TAT had greater
efficacy relative to 213Bi-TAT
with specific tumor uptake
and minor renal toxicity.
[153,154]















E4G10 Ab 225Ac–DOTA–E4G10, i.v.
LS174T human colon s.c.
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U87 MG human glioblastoma







225Ac BD, Efficacy Thrombo-modulin 201b mAb
LnPO4 nanoparticles (NPs) doped
with 225Ac-201b, i.v.
Syngeneic EMT6 mouse breast
epithelial cell metastases in
BALB/c mouse lung following i.v.
injection of cells
Retention of 225Ac and
daughters in lung tissue,
metastasis burden reduced.
[157]
225Ac Micro BD, RD PD-L1 anti-PD-L1-BC Ab 225Ac–DOTA–anti-PD-L1-BC, i.v.
NT2.5 mouse mammary
xenografts in female nude mice.
Uniform distribution in
liver, non-uniform in kidney
and tumor, liver RD
was limiting.
[158]
225Ac BD and toxicity Bone metastasis
Zoledronic acid
(ZOL)











LNCaP human prostate cancer s.c.
xenografts in BALB/c mice.
Decreased clearance rate,
single administration had







MC1R MC1RL peptide 225Ac–DOTA–MC1RL, i.v.
PK (Sprague-Dawley rats),
BALB/c mice (toxicity and BD)
and MEL270 human uveal
melanoma s.c. xenografts in SCID








225Ac Efficacy, toxicity CA19.9 5B1 human mAb
225Ac-labeled tetrazine radioligand




















E4G10 Ab 225Ac–DOTA–E4G10, i.v.
LS174T human colon s.c.
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toxicity. RD estimates. [161,162]
211At
PK, BD, efficacy,
toxicity gp38 MOv18 mAb
211At- & 131I-MOv18, i.p. or i.v.
Peritoneal OVCAR-3 human
ovarian xenografts in BALB/c ν/ν
or nude mice following IP
injection of cells.
211At-TAT had greater









Murine F9 teratocarcinoma & rat
FE8 sarcoma in female nude mice.











211At-MX35, i.p. or i.v.
OVCAR-3 human ovarian cancer







Efficacy CD30 HeFi-1 mAb 211At-, 90Y HeFi-1, i.v.
Human anaplastic large cell
lymphoma cells in SCID/NOD
mice. Karpas 299 cell i.v. injection
for leukemia & SUDHL-1
xenografts for lymphoma.
211At-HeFi-1 increased
survival in the leukemia









toxicity CD44v6 U36 chimeric mAb
211At-U36, i.v.
UT-SCC7 human head and neck
squamous cell carcinoma s.c.
xenografts in nude mice.
Reduced tumor growth










xenografts in nude mice.
Tumor growth delay with







NIS transduced LNCaP human
prostate (NP-1) and parental (P-1)
s.c. xenografts in male nude mice.
Accumulation similar to
iodine with efficacy against
NP-1 tumors relative to
control P-1 tumors.
[147]
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greater efficacy and less
toxicity relative to the
213Bi conjugate.
[171]
211At Efficacy HER-2/neu Trastuzumab 211At-trastuzumab, i.p.
SKOV3 human ovarian i.p.




















211At Efficacy CD20 1F5 mAb 211At-1F5, i.v.
Human Ramos (Burkitt
lymphoma) s.c. xenografts in
nude mice and i.v. injection of
Ramos cells in SCID mice for
disseminated lymphoma.




211At BD, dosimetry Sigma-2 receptor MM3 ligand 211At-MM3, i.v.
EMT6 murine breast syngeneic






PC12 rat pheochromocytoma s.c.
xenograft in nude mice.
Reduced tumor size
without weight loss. [174]
211At BD, efficacy MICA/B anti MICA/B Ab 211At-anti MICA/B Ab, i.v.
HCT116 (p53-/- & MICA/B
positive) human colon cancer s.c.
xenograft in nude mice.
Significant reduction in
tumor growth, no weight
loss, erythrocytopenia with





efficacy CO17-1A CO17-1A Fab’
213Bi-Fab’ and 90Y-Fab’, i.v.
GW-39 human colon cancer s.c.
xenograft in nude mice.
TAT had greater efficacy
and lower toxicity than TBT. [176]
212Bi
Specificity, efficacy,
toxicity gp70 103A mAb
212Bi–CHX-A-DTPA–103A, i.v.
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SP2 and SP2/Tac syngeneic
murine lymphoma in nude mice.
Effective in treatment of
bulky solid tumors. [178]
213Bi
Stability, PK,

































213Bi- or 131I-HuCC49∆CH2, i.p.
TAG-72+ LS-174T & TAG-72
negative MIP human colon i.p.






213Bi Efficacy, toxicity d9-E-cad d9-E-cad mAb 213Bi-d9-E-cad mAb, i.p.
HSC45-M2 human gastric i.p.
xenografts with d9-E-cad
mutation in female nude mice.
Double administration had

















213Bi Specificity, BD CD87 P-P4D peptide 213Bi-P-P4D, i.p.
OV-MZ-6 human ovarian i.p.
xenografts in female nude mice.
Specific tumor uptake,









213Bi-C595, -BLCA-38 & -PAI2, i.p.
PC-3 human prostate orthotopic,
intratibial and s.c. xenograft
tumors in NOD SCID mice.





213Bi Efficacy, toxicity EGFR Matuzumab 213Bi-matuzumab, intravesical
EJ28 human orthotopic bladder











LS-174T human colon i.p.
xenografts in female nude mice.
Combination trastuzumab










1F5-SA & 213Bi–DOTA–biotin, i.v.
Ramos human lymphoma
xenografts in nude mice.
Tumor regression and
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PC-3 human prostate s.c.





lower renal toxicity relative
to 213Bi-AMBA.
[185]
213Bi, 177Lu Efficacy CD138 9E7.4 mAb 213Bi-9E7.4 and 177Lu-9E7.4, i.v.
5T33 murine multiple myeloma
cell syngeneic i.v. injection into
C57/BL6 mice.
213Bi-9E7.4 increased




213Bi, 177Lu Efficacy, toxicity
Mutant
d9-E-cadherin d9MAb
213Bi-d9Mab & 177Lu-d9Mab, i.p.
HSC45-M2 human gastric cancer
cell i.p. injection in nude mice.
213Bi had comparable








5T33 mouse multiple myeloma






213Bi Efficacy, toxicity EGFR Matuzumab 213Bi-matuzumab, intravesical.
EJ28 human orthotopic bladder










small cell lung carcinoma and
CA20948 rat pancreatic s.c.
xenografts in nude mice.
Effective in small and large
tumors (both types), with
dose limiting renal toxicity.
[66]
212Pb Efficacy HER-1 Cetuximab 212Pb-cetuximab, i.p.
ILS174T human colon i.p.






















A-431 HER-2 positive and CEA
transfected vulvar squamous
carcinoma cells i.p in nude mice.
Internalizing anti-HER2





212Pb Efficacy, toxicity HER-2/neu Trastuzumab 212Pb-trastuzumab, i.p.
LS174T human colon & Shaw
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Isotope Study Molecular Target Targeting Moiety Drug(s) & Route Cancer Type & Animal Model Key Results Ref
212Pb Efficacy HER-2/neu Trastuzumab 212Pb-trastuzumab, i.p.
LS-174T human colon i.p.





212Pb BD, efficacy B7-H3 376.96 mAb 212Pb-376.96, i.p.
ES-2 or A2780cp20 human










High tumor uptake &
tumor growth inhibition. [196]
212Pb BD, efficacy CSPG4 225.28 mAb 212Pb-225.28, i.v.
SUM159 & 2LMP human triple
negative breast cancer (TNBC)
orthotopic mammary fat pad








212Pb-panitumumab F(ab’)2, i.p. &
i.v.
ILS-174T human colon i.p.
xenografts in nude mice.
Increased survival with





















BALB/c mice & Raji human B-cell








SKBR-3 human breast cancer
xenografts in nude mice.
Tumor growth inhibition






786-O human renal cancer s.c.
xenografts in nude mice
Well tolerated with








ES-2 and SKOV3 human ovarian
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7. Pre-Clinical Studies
7.1. Preclinical Therapeutics Studies
In recent years, a number of pre-clinical studies have been reported that provide strong evidence
of the potential for use of TAT in the treatment of cancers. See Table 2 for a summary of the
published in vivo preclinical TAT studies (n = 48) that have used animal models of cancer. Most of
these studies (81%) have involved the use of immunoconjugates where monoclonal antibodies serve
both as the targeting moiety and as the attachment scaffold for the α-emitting radionuclide. Two of
these immunoconjugates involved the use of antibody fragments (scFv) [140,141] and one used a
diabody [142]. Three studies involved pretargeting, where a cancer targeting antibody–streptavidin
construct, or antibody–TCO (trans-cyclooctene) construct for click chemistry, was injected prior to
delivery of an α-emitting radionuclide attached to biotin [141,143,144]. In this study, pre-targeting
demonstrated increased efficacy over TAT using the targeting antibody alone. Peptide-based targeting
moieties were used in 15% of these studies. In other individual studies, a protein [145], a small molecule
ligand [146] and an inorganic compound [147] were used as targeting groups.
As is the case for most radioimmunotherapies in current use, that typically deliver β-emitting
radionuclides, a number of the reported TAT studies (23%) targeted non-solid tumors; i.e., leukemias,
lymphomas and multiple myeloma. A majority of these non-solid tumor studies reported significant
efficacy and/or decreased systemic toxicity relative to controls. Since α-emissions have higher LET
over a shorter range, there is significant interest in the use of TAT for treatment of solid tumors. This is
evident in the preclinical studies reported, as 79% involved targeting of solid tumors and nearly all of
these studies reported significant efficacy against solid tumors relative to controls, with nearly half also
reporting low or manageable systemic toxicity. Four of these studies demonstrated increased efficacy
using TAT relative to targeted beta (β)-emission therapy (TBT) using the same targeting moiety and
tumor model [143,151,152,163–166,180,185].
7.2. Preclinical Imaging
Whether developing a small molecule or antibody-based therapeutic, pharmaceutical companies
traditionally rely upon molecular imaging to assist them in identifying the most promising molecules
in the research pipeline to be carried forward into clinical trials [203–206]. Furthermore, this strategy
has been particularly effective in developing targeted, systemic β-based radiotherapies when the
β-emitting radioisotope can be paired with a diagnostic surrogate for SPECT or PET imaging. Several
of these pairs include 64/67Cu, 86/90Y and 124/131I [207]. However, with the exception of the 203/212Pb
system [68,191,208], researchers developing TATs with other α-emitters such as 213Bi, 211At and 225Ac,
have not been able to capitalize on this strategy. This limitation has hindered TAT development,
but also stimulated attempts by the scientific community to observe the pharmacokinetics of TAT
therapies using the decay of TAT radioisotopes in preclinical or clinical settings. For example, Sgouros
et al. attempted to use the 440 keV γ emission of 213Bi to monitor the biodistribution of 213Bi-HuM195
in patients with leukemia [209]. Due to the short half-life of the radioisotope, data acquisition was
limited to sixty minutes after patient injection, but this was sufficient to detect elevated levels of
radioactivity in the red marrow, liver and spleen. While the data suggested that it would be possible to
derive important pharmacokinetic and dosimetric data from the in vivo imaging of the 213Bi emissions,
the large amount of activity necessary for imaging has precluded its routine use in a clinical setting.
The decay scheme and extreme cytocidal potency of 225Ac further complicates the TAT community’s
ability to develop preclinical and clinical imaging methodologies to monitor pharmacokinetics and
estimate dosimetry. Since the 440 keV emission derived from 213Bi decay is considered too energetic for
preclinical imaging applications, attention has focused on the less energetic 218 keV γ ray emission of
221Fr, which has been used to monitor the biodistribution of 225Ac-doped nanoparticles in mice [71,86],
and this approach has shown promise. However, in this imaging paradigm, animals are typically
euthanized 1 h after receiving the radiopharmaceutical and imaged 24 h after euthanasia to ensure
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isotopic equilibrium. Hence, these experiments do not address the potential of longitudinal SPECT
studies to inform development of 225Ac-radiopharmaceuticals. Clearly, new approaches are needed,
since the ability to image and visualize 225Ac-based radiopharmaceutical biodistribution, metabolism,
and clearance in animal models through longitudinal imaging studies would be advantageous [210,211].
Cerenkov luminescence imaging has emerged as an alternative to traditional nuclear medicine
techniques for visualizing the delivery and biodistribution of TATs. Cerenkov luminescence is derived
from the emission of ultraviolet light when certain charged particles exceed the phase velocity of
light in a given medium [212,213], and this effect can be observed using standard optical imaging
systems originally designed to detect bioluminescence and fluorescence. Recently, Cerenkov emissions
were observed with the decay of several medically relevant isotopes, including 225Ac, which was
reported to yield the largest optical signal among all isotopes examined [211,214]. Alpha (α) particles
however, do not travel with sufficient velocity to generate Cerenkov emissions, which led researchers
to postulate that the emissions observed resulted from the β-decay of the 213Bi, 209Tl and 209Pb
daughter products. Subsequent publications, using theoretical and experimental means, described
the association between Cerenkov radiation and 225Ac decay [214,215]. While both research groups
determined that Cerenkov luminescence imaging (CLI) could be accomplished with 225Ac and other
α-particle emitting radionuclides, it was determined that radionuclides’ decays solely by α-particle
emission do not produce sufficient Cerenkov radiation to be useful for imaging. Secondly, a time
delay would be needed for equilibrium to be established between the parent radionuclide and its
daughter products. For 225Ac, this delay was determined to be ten hours. This precludes the imaging
of small molecules and peptides at early time points, but allows one to monitor the biodistribution of
225Ac-labeled antibodies and nanoparticles, which require extended circulation time for effective tumor
targeting and blood clearance. Finally, the high recoil energy associated with 225Ac and daughter
product release from the original conjugate must be considered. The emission of Cerenkov radiation
may not reflect the actual biodistribution of the radiopharmaceutical in question, but of the daughter
products producing the Cerenkov emissions [216]. Sequestering the daughter products with the
original conjugate is important if this technique is to provide any benefit to the TAT community.
In proof of principle studies, Pandya and coworkers seized upon these recommendations and further
tested the association between 225Ac decay and Cerenkov radiation in living animals [217]. The authors
synthesized 225Ac–DOTA–c(RGDyK) and evaluated its stability, biodistribution and potential use
as an imaging agent in CLI in a murine model expressing human glioblastoma U87mg tumors,
which overexpress the αvβ3 integrin. Additionally, they exploited the well-documented ability of
RGD-containing ligands to be internalized on integrin binding to sequester the 225Ac and the daughter
products within the tumor. This technique, often referred to as the nanogenerator approach, has been
used successfully to sequester 225Ac-based radiotherapeutics and daughter decay products within a
cell to increase their therapeutic effectiveness [35,149,150]. Surprisingly, all animals demonstrated no
signs of distress during these experiments. When compared to αvβ3- tissues, in vivo CLI revealed
five-fold more luminescence from the αvβ3+ tumors. Luminescence was also observed in the liver and
kidney tissues, which have been shown in related biodistribution studies to be involved in the clearance
and excretion of this radiopharmaceutical [218–220]. Ex vivo image analysis also revealed a similar
trend as the in vivo results, and the addition of a blockade reduced the luminescence emitted from the
tumors by 80%, which suggested to the authors that activity delivered by the radiopharmaceutical and
internalized through specific receptor-interactions was being retained in the tumor. To further validate
the theranostic potential of their approach, they also performed preliminary therapy studies in U87mg
tumor-bearing mice, which illustrated the cytocidal potency of their α-emitting radiotherapeutic [221].
While more studies are needed, these promising results suggest that this area of research may have
broader implications for molecular imaging and may help to facilitate TAT development.
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8. Medicinal Chemistry
8.1. Lead Optimization
As previously touched upon, the characteristics of various targeting ligands, like lipophilicity,
molecular weight and ionization potential are all critical variables that help modulate
radiopharmaceutical properties. For example, small, polar compounds may undergo rapid renal
excretion. The addition of a PEG linker will add water solubility, bulk, and may help avoid kidney
toxicities. Conversely, the removal of an ionizable group (e.g., sulfonate or protonated amines at
physiologic pH) during medicinal chemistry design may make the targeting ligand more hydrophobic
and shift clearance toward initial liver processing. Therefore, when working to reduce targeting ligand
complexity or increase the ease of synthesis, these physical attributes of the compound must be taken
into consideration.
Antibodies and engineered fragments can also benefit from medicinal chemistry optimization.
Many chelators and linkers covalently attached to antibodies and their fragments produce
heterogeneous products. In the most typical fashion of linker attachment, surface accessible lysine
side chains are utilized to form covalent bonds with radionuclide chelating molecules (Figure 6).
Site-specific antibody modifications can yield more homogeneous products. The Rader group at Scripps
Florida has made such progress by engineering a selenocysteine residue into targeting antibodies,
allowing for complete control of regiochemistry during functionalization [222].
Another route to increasing T/NT ratios is through the notion of pretargeting. These strategies
operate under the premise that nonradiolabeled, bifunctional targeting agents can be administered
to the patient and allowed to converge to their target. Once the unbound portion has cleared,
a fraction of radiolabeled molecule with a binding affinity for the bifunctional targeting agent is
administered. Typically, the radiolabeled agent is designed to clear quickly if unavailable for binding;
thus, lowering off-target radiation. Typical binding partners amenable to pretargeting schemes include
avidin/streptavadin–biotin, DNA–DNA or antibody–hapten [223]. For a more in-depth analysis of
pretargeting strategies please see the recent review article from Frampas and coworkers [224].
Novel combination therapies are also now being investigated. Combination therapies can be
particularly useful in heterogeneous diseases like multiple myeloma. Anti CD138 mAb conjugated with
213Bi has been tested synergistically with the chemotherapeutic melphalan to help eliminate residual
disease in a multiple myeloma model [116]. Interestingly, this study saw no benefit to the combination
therapy when compared with RIT alone. The speculation was that the follow-up treatment with
CD138-targeted mAb was less successful due a swift reduction in CD138 antigen in cells progressing
through apoptosis [225], illustrating the importance of the orthogonality in study design as it relates to
combination treatments and target expression.
8.2. cGMP Production
Current good manufacturing practice (cGMP) standards for the production of the targeting ligand
precursors before the incorporation of the α-emitting radioisotopes are similar to those used for the
manufacturing of peptide, antibody or antibody fragment drug and drug candidates. There are
numerous cGMP-compliant peptide synthesis companies, and often the preclinical grade peptides
will be prepared by standard solid-phase synthesis and purified to ≥ 95% purity, but cGMP-grade
peptides will often be prepared via routes that allow greater control over the purity and reliability of
the synthesis. For instance, cGMP peptides are more likely to be prepared using a greater reliance on
solution phase-synthesis procedures than preclinical grade peptides because the costs can be much
lower on scaled-up batches of peptide, and more importantly, impurities can be removed as they build
up during a solution-phase synthesis, whereas impurities just build up during standard solid-phase
synthesis procedures. The recent development of a fully solid-phase synthesis of cGMP-quality
Fuzeon® is an exception to this trend that may lead to a greater reliance on fully solid-phase synthesis
procedures for the production of cGMP peptides. Frequently, solid phase methods are used in
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combination with solution phase synthesis methods. As an example, preclinical grade linear peptides
can be prepared and cyclized to the final product on resin, whereas cGMP grade peptides will often be
prepared on resin and purified and then cyclized in solution, due to the easier analysis of reactions
in solution.
The cGMP production of antibody and antibody fragments will be focused on for the development
of robust methods of production often using hybridoma technologies and purification by at least two
orthogonal separation methods, usually involving an affinity column purification step followed by
a size exclusion type purification system. Often these biotechnology-based manufacturing methods
produce antibody or antibody fragments that are chemically programmed to provide specific sites
for metal chelate attachment. For a recent review of this topic please, see the two-part article from
Adumeau et al. [226,227].
The results of these manufacturing processes are lyophilized powders or relatively-concentrated,
sterile, aqueous buffer solutions of the targeting moieties that are ready to chelate the α-emitters.
The main difference between cGMP radiosynthesis for clinical trials and research grade radiosynthesis
in the United States is the implementation of an FDA-compliant audit trail. Since the development of
α-emitting radiopharmaceuticals is happening globally, another major issue concerning production
and distribution of these novel therapies is the consideration of the local regulatory environment.
A discussion of the potential for harmonization of the various international regulations has recently
been published [228].
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Table 3. Clinical TAT studies.
Isotope MolecularTarget
Targeting
Moiety Drug Cancer Type Trial/# of Patients
Administration
Route Key Results Ref





Safe at doses ≤ 3 µCi/kg,
anti-leukemic activity across all






225Ac–PSMA-617 Prostate cancer NA/40 Intravenous
Remarkable anti-tumor response
was observed in the patients.
Xerostomia in salivary gland was















211At-ch81C6 Glioblastoma Phase I/18
surgically created
resection cavity
Increased Median survival (54
weeks), No dose-limiting toxicity,
No-grade 3 toxicity
[238]
211At NaPi2b MX35 F(ab′)2 211At-MX35 F(ab′)2
Ovarian
carcinoma Phase I/9 Intraperitoneal
No adverse effects, grade I toxicity,
no bone marrow toxicity [239]
213Bi CD33 HuM195 213Bi–CHX-A-DTPA–HuM1 95 AML Phase I/18 Intravenous
14 patients had reductions in
marrow blasts [240]
213Bi CD33 HuM195 213Bi–CHX-A-DTPA–HuM1 95 AML Phase I, II/31 Intravenous
dose-response relationship with
remission at the highest doses [241]
213Bi CD20 Rituximab 213Bi-CHX-A”- Rituximab
Non-Hodgkin
lymphoma Phase I/9 Intravenous
Myelosuppression and no other
toxic side, two patients responded [242]
213Bi
Neurokinin
type-1 receptor Substance P
213Bi–DOTA–[Thi8, Met (O2)
11]–substance P




213Bi–cDTPA–9.2.27 Melanoma Phase I/38 Intralesional
TAT was safe up to 450 mCi and








tumors NA/7 Intraarterial infusion
responses were observed in
all patients [65]
213Bi EGFR Cetuximab 213Bi–CHX-A-DTPA–anti-EGFR
carcinoma in
situ (CIS) of the
bladder
Pilot studies/9 and 12 Intravesical TAT well tolerated and showedtherapeutic efficacy [231,232]
212Pb HER2 Trastuzumab 212Pb–TCMC–trastuzumab Ovarian Cancer Phase I/3 Intraperitoneal
Dose escalation showed a little
agent-related toxicity, consistent
with the dosimetry data
[246,247]
223Ra Hydroxy-apatite NA 223Ra–chloride
Prostate cancer
mets Phase I-III/921 Intravenous
radium-223 improved
overall survival [7,8,82,248–251]
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9. Clinical Studies
9.1. Recent TAT Clinical Trials
Despite the potential therapeutic benefits of the α-particle emitting radioisotopes over β-particle
emitters, the restricted availability of relevant radionuclides and limited number of phase III clinical
trials has so far limited the clinical use of TAT. Table 3 summarizes the TAT clinical studies conducted
to date. Clinical trials prior to 2014 were reviewed by Elgqvist et al. [34] and we will focus on the more
recent trials herein. The use of short-lived α-emitters like 211At (T1/2 = 7.2 h), 212Bi (T1/2 = 60 min) and
212Pb (T1/2 = 10.6 h) has been subdued so far, due to production and distribution limitations. However,
this is not the case for 213Bi (T1/2 = 46 min), which, going back over the past two decades, has been used
in the largest number of TAT clinical trials to date. Recent 213Bi studies have included the targeting
of peptides for the treatment of glioblastoma [229,230] and neuroendocrine tumors [65], and the
targeting of monoclonal antibodies for the treatment of bladder cancer [231,232]. Since the approval of
223Ra-dichloride for the treatment of CRPC in 2013, 225Ac has also emerged as a targeted therapeutic
radionuclide of interest that has been used for targeting a small molecule [5,6,233], peptide [234] and
monoclonal antibody [235] for the targeting of prostate cancer, neuroendocrine tumors, and acute
myeloid leukemia (AML), respectively. Clinical studies of TATs using 225Ac or 213Bi as the therapeutic
radionuclide have recently been reviewed [58]. Although the responses have been impressive for some,
225Ac–PSMA-617 in particular, the completion of more randomized clinical trials comparing TAT to
standard of care will be essential to determine the clinical utility of these new therapeutic approaches.
9.2. Radium-223 Dichloride (223RaCl2) Trials
In the following section, we will discuss the first and only clinically-approved TAT in the United
States so far. After more than a 100 years since the discovery of the radium element in 1898 by Marie and
Pierre Curie, on May 15, 2013, one of its radioisotopes, radium-223 (Ra-223) became the first α-emitting
radionuclide to be approved by the Food and Drug Administration (FDA) in the form of radium-223
dichloride (223RaCl2, Xofigo® formerly Alpharadin, made by Bayer HealthCare Pharmaceuticals Inc.)
for the treatment of patients with castration-resistant prostate cancer (CRPC), with symptomatic bone
metastases, and no known visceral metastatic disease [252]. This was based on the improvement in
overall survival following intravenous administration of 223RaCl2 in patients with advanced prostate
cancer with metastases to the bone, demonstrated in a double-blind randomized placebo-controlled
trial called the ALSYMPCA (alpharadin in symptomatic prostate cancer) trial [7].
The role of systemic radionuclide therapy to the bone is to deliver therapeutically-effective radiation
doses to multiple foci, including microscopic disease, as opposed to external beam radiotherapy,
that gives more focal treatment and affects both normal bone marrow and metastases [253]. The two
most commonly used radionuclide bone seeking agents for bone pain palliation are 89Sr (Metastron)
and 153Sm-ethylene diamine N,N′-tetra(methylene) phosphonic acid (153Sm-EDTMP; Quadramet) [254],
but these β-particle therapies, although effective for pain palliation, frequently cause myelosuppression
and have not been shown to affect patient survival [255].
Cations of the alkaline earth elements (strontium, barium, and radium) have natural bone-seeking
properties without the need for a carrier agent. As radium mimics calcium, when Ra-223 dichloride
is injected intravenously, it forms complexes with the bone mineral hydroxyapatite at areas of
increased metabolic bone activity, such as bone metastases, thereby exerting a highly localized
antitumoral effect [7,256]. In addition, the Ra-223 daughter isotopes are also retained in the bone
matrix [50]. The shorter penetration range of Ra-223 causes less bone marrow toxicity than bone-seeking
β-particles [256]. The peak skeletal uptake of Ra-223 occurs within 1 h of injection, and blood
radioactivity levels are <1% after 24 h with almost no redistribution of daughter nuclides from
bone [256]. The total skeletal uptake ranges between 40% and 60% of the administered activity [257],
and the excretion is predominantly via the gastrointestinal tract, with much less renal clearance [258].
Due to their significantly higher potency, the activities administered of α-emitters are much lower
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than β emitters, with significantly less radiation exposure to hospital staff and family members [259].
Merely basic hygiene measures and routine contamination protection barriers, such as latex gloves,
are enough to protect both health care personnel involved in the patient’s radionuclide administration
and the patient’s family.
In the first-in-human single dosage phase I trial for patients with breast and prostate cancer skeletal
metastases, single dose Ra-223 was well tolerated at all therapeutically relevant doses (46–250 kBq/kg
intravenously [IV]) [257]. There was no dose-limiting hematological toxicity, only mild, transient
myelosuppression (nadir 2 to 4 weeks after the injection) and mild transient diarrhea, with nausea
and vomiting more frequently observed in the highest dosage group [257]. Subsequently, the phase I
dose-escalation study in advanced prostate cancer with bone metastases, showed that repeated Ra-223
dosing was well tolerated to a total dose of 250 kBq/kg [50].
In the following phase II study of CRPC patients with symptomatic bone metastases, Ra-223
given at different doses (5, 25, 50 and 100 kBq/kg) was well tolerated with a positive effect on pain
assessments (visual analogue scale [VAS] and analgesic use). At week 8, 56% and 71% of patients
had reduced pain and stable analgesic consumption in the 50 and 100 kBq/kg groups, respectively.
A statistically significant decrease in bone turnover markers, including alkaline phosphatase, was noted
in the highest dose-group (p = 0.0067) [260].
The phase III, double-blind, randomized, placebo-controlled, multicenter, multinational
ALSYMPCA trial enrolled patients from June 2008 through February 2011 [7]. Eligible patients
had progressive metastatic symptomatic disease and regular use of analgesic medication or treatment
with external beam radiation therapy (EBRT) for cancer-related bone pain within the previous 12 weeks.
Patients were randomized 2:1 to receive six injections of radium-223 (50 kBq/kg IV) or a saline placebo
infusion; a cycle was comprised of one injection every 4 weeks. The primary endpoint was overall
survival (OS). Various secondary endpoints included time to first symptomatic skeletal events (SSE),
time to alkaline phosphatase increase and time to PSA progression. A planned interim analysis was
conducted, and on June 3, 2011, the Independent Data Monitoring Committee recommended stopping
the trial early due to evidence of a significant treatment benefit. Median OS was 14.0 months for Ra-223
(95% CI (confidence interval): 12.1–15.8) versus 11.2 months for placebo (95% CI: 9.0–13.2) (p = 0.00185;
HR (hazard ratio) = 0.695; 95% CI: 0.552–0.875).
An updated analysis included 528 events from 921 randomized patients prior to placebo patients
crossing over to Ra-223 [7,261]. For this analysis, median OS was 14.9 months for Ra-223 arm (95%
CI: 13.9–16.1) and 11.3 months for patients receiving placebo (95% CI: 10.4–12.8) (HR = 0.695; 95% CI:
0.581–0.832). OS favored Ra-223, with a 30% reduction in the risk of death compared with placebo.
The OS benefit with Ra-223 was supported by a delay in time to first SSE compared to the placebo (15.6
versus 9.8 months; HR = 0.66; 95% CI, 0.52–0.83; p < 0.001). Improvement in survival was independent
of both prior exposure to docetaxel [250] and the use of bisphosphonates [261]. Ra-223 significantly
prolonged time to total ALP progression (HR = 0.167; 95% CI: 0.129–0.217; p < 0.00001); and time
to PSA progression (HR = 0.643; 95% CI: 0.539–0.768; p < 0.00001) was associated with a beneficial
effect on pain and quality of life (QOL) [262], and was associated with a highly favorable safety profile
with a low rate of adverse hematological events. The most common (at least two percent) of the
adverse reactions in patients receiving Ra-223 were nausea, diarrhea, vomiting, renal impairment and
peripheral edema.
Based on these data, the National Comprehensive Cancer Network (NCCN) supports the use
of 223RaCl2 (Xofigo®) as a first-line therapy for patients with symptomatic metastatic CRPC and no
visceral metastases with a Category 1 recommendation [227]. The recommended dose for 223RaCl2 is
50 kBq/kg (1.35 microcuries/kg) administered by slow intravenous injection, over 1 min, every 4 weeks,
for a total of six cycles.
Since completion of the ALSYMPCA trial, Ra-223 has been studied in combination with
other, newly-approved CRPC therapies, such as abiraterone, enzalutamide, docetaxel, cabazitaxel,
sipuleucel-T, olaparib and pembrolizumab [263–265]. A phase 3, randomized, double-blind study of
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radium-223 or placebo, each in combination with abiraterone plus prednisone in chemotherapy-naive
patients with asymptomatic or mildly symptomatic mCRPC with bone metastases (ERA 223;
NCT02043678) [266], was recently prematurely unblinded. The independent data monitoring committee
(IDMC) recommended unblinding the trial due to the observation of more fractures and deaths in
the combination treatment arm. The European Medicines Agency (EMA)’s Pharmacovigilance Risk
Assessment Committee (PRAC) has reviewed the preliminary data from the ongoing clinical study.
In the study 34.7%, of patients treated with Xofigo, Zytiga and prednisone/prednisolone have died so
far, compared with 28.2% of patients given placebo, Zytiga and prednisone/prednisolone. Fractures
have also occurred more frequently with the Xofigo combination than the placebo combination (26%
versus 8.1%). Unblinded data from the study are currently being analyzed to confirm the preliminary
findings of the IDMC. Given these results from ERA 223 trial, the current recommendation is not to
combine radium-223 with concomitant abiraterone acetate and prednisone (https://www.ema.europa.
eu/news/prostate-cancer-medicine-xofigo-must-not-be-used-zytiga-prednisoneprednisolone). Hence,
the administration of concomitant chemotherapy with Xofigo is not recommended due to an increased
risk of adverse reactions [267].
Immune modulation has been examined in vitro in human prostate, breast and lung carcinoma
cells following exposure to sub-lethal doses of 223Ra. Malamas and his colleagues showed that 223Ra
significantly enhanced T cell-mediated lysis of each tumor type by CD8+ cytotoxic T lymphocytes
(CTLs) specific for MUC-1, brachyury, and CEA tumor antigens. Therefore, 223Ra may be more effective
in combination with immunotherapies [268].
In view of the increased long term risk of secondary malignancies, such as sarcomas and leukemias,
that were seen in patients who were treated with high doses of another radium isotope, radium-224
(T1/2 = 3.7 days) (primarily used in Europe) for bone pain associated with ankylosing spondylitis, there
is concern for development secondary malignancy with the use of Ra-223. So far there has been no
evidence of secondary malignancies following Ra-223 therapy [7,269]. However, it is important to note
that patients with metastatic CRPC have a much shorter overall survival than patients with ankylosing
spondylitis. Care should be taken when expanding the use of Ra-223 to other patient groups with
longer expected overall survival times, since the rate of secondary tumor development may increase.
Ra-223 trials have been performed for patients with diseases other than CRPC. Ra-223 was found
to be safe and well tolerated when studied in a phase II, open-label trial investigating the safety and
short-term efficacy in patients with breast cancer who had bone-dominant disease [270], but the data
are still limited. In contrast to prostate cancer, multiple myeloma bone lesions are predominantly lytic.
It is not yet know if Ra-223 will have any role in this category of patients, but based on previous clinical
trials using 153Sm-EDTMP plus chemotherapy, the combination showed efficacy in some patients
with far-advanced myeloma [271], so theoretically, these results could be replicated with Ra-223,
with potentially fewer side effects. In view of the limited but positive experience in 153Sm-EDTMP for
osteosarcoma due to its osteoblastic nature [272], there is currently a phase I dose trial for the use of
Ra-223 in patients with osteosarcoma at the M.D. Anderson Cancer Center (www.clinicaltrials.gov;
NCT01833520).
10. Conclusions
There has recently been significant interest and progression toward the development of targeted
alpha-particle therapy (TAT) for the treatment of solid tumors. Many pre-clinical and clinical studies
have demonstrated promising anti-tumor efficacy results (Tables 2 and 3). The success of 223RaCl2
in the care of patients with bone metastases and the apparent efficacy of additional TAT agents in
recent clinical studies, e.g., 213Bi–DOTATOC and 225Ac-PSMA, has brought attention to this area
of radiopharmaceutical development and increased the potential for successful translation of TAT
for treatment of solid tumors and metastases [65,233]. Three radioisotopes have seen the most use
in preclinical and clinical studies, 213Bi, 225Ac and 211At. Each of these radionuclides has distinct
advantages and disadvantages regarding availability, cost, decay chain attributes, tissue distribution
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and stability of attachment. Of these, 225Ac is readily available and has the distinct advantage of
having a long, 10 d half-life, which allows for centralized production and distribution compared to the
requirement of local production for the other radionuclides with shorter half-lives. Since TAT does not
rely on the generation of free-radicals for the generation of DNA damage, as is the case for β-emission
therapies, a major mechanism of resistance to radiation treatment can be bypassed; i.e., upregulation
of superoxide dismutase. Some evidence of this was seen in a report stating that patients with
tumors that have developed resistance to 90Y/177Lu–DOTATOC therapy were sensitive to subsequent
treatment with 213Bi–DOTATOC [65]. Additionally, the use of α-emitters enables solid-tumor targeted
therapy with decreased peripheral tissue damage and the potential for decreased development of
resistance due to the ability to kill surrounding tumor cells that do not express the target marker in a
heterogeneous tumor microenvironment. Small molecules, peptides and monoclonal antibodies have
been used for tumor targeting (Tables 2 and 3). However, due to the shorter clearance time (minutes
to hours), small molecules and peptides may have an advantage over antibodies that can circulate
for days in that they can accumulate in the target tumor and clear systemically prior to decay and
deposition of energy, maximizing the beneficial effects of the ionizing radiation while minimizing the
off-target exposure. This is especially true when using radionuclides with a long half-life; e.g., 225Ac.
Peptide-targeted agents may have a greater risk of generating renal toxicity [66], but there is evidence
that lead optimization via medicinal chemistry could potentially improve the renal toxicity of a given
peptide agent. For example, a recent preclinical study of two different gastrin-releasing peptide receptor
(GRP-R)-targeting agents using two different 213Bi-labeled GRP-R targeting peptides demonstrated
differential renal toxicities [185]. TAT is currently emerging as a potentially new and effective approach
toward the treatment of solid tumors, and the clinical translation of novel TAT radiopharmaceuticals
appears to be on the near horizon. Since the abscopal effect has been observed in external beam therapy
in animals, the ability to target internal radiation to tumors via TAT may have additional added value
as a companion to the recently-successful immune checkpoint targeted therapies.
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